U.S., Nov. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07225335) titled 'Impact of OptiCreatine on Plasma Creatine and Gastrointestinal Effects in Males and Females' on Nov. 03.
Brief Summary: The study aims to evaluate the novel OptiCreatine formulation, which combines creatine with other bioactive compounds purported to enhance absorption and reduce gastrointestinal (GI) discomfort. Using a randomized, double-blind, crossover design, the study will compare the acute and chronic effects of OptiCreatine versus Creatine monohydrate in healthy, recreationally active adults. Participants will be asked to orally consume both the OptiCreatine and the creatine monohydrate. Primary outcomes include plasma creati...